Early Vascular Ageing (EVA) – 2019-opdatering

​​Steno Rounds den 25. april 2019 med professor Peter M. Nilsson, Lund Universitet, Malmö, Sverige. Foredraget er på engelsk.

Foredraget i videoen er på engelsk, og derfor er nedenstående beskrivelse også på engelsk.

Early Vascular Ageing (EVA) – an update 2019

Arterial stiffness, the core feature of Early Vascular Ageing (EVA), is known to be strongly associated with age and hypertension, findings also confirmed in a longitudinal study in Framingham. In some individuals, the arterial stiffening seen with increasing age is more pronounced and occurs earlier in life, a phenomenon described as EVA. A number of non-haemodynamic components are thought to affect the arterial ageing, among the markers of glucose metabolism and insulin resistance influencing dyslipidaemia.

Several cross-sectional studies have shown an association between arterial stiffness and diabetes as well as with markers of impaired glucose metabolism. Individuals with end-stage renal disease are also known to exhibit an increased central arterial stiffness but results from studies investigating the association between arterial stiffness and stages of chronic kidney disease have presented conflicting results.

New aspects of EVA is early life programming, genetics, mircobiota and chronic inflammation. New intervention studies test the benefits of reducing arterial stiffness in a targeted way, for example the SPARTE study in France. More recently a focus has also been developed to address the non-EVA subjects with relatively healthy vascular ageing in spite of chronological ageing. If we can better understand the mechanisms of protection this could eventually turn into new drug targets.